Novo Nordisk stock news
On November 2, 2026, Novo Nordisk expanded the commercial availability of its once--daily oral Wegovy (semaglutide) tablet for obesity, rolling out the treatment in Poland and France. The commercial launch in these markets follows earlier European introductions in the United Kingdom and Germany as Novo Nordisk seeks to scale its oral GLP--1 franchise ahead of announcing its third--quarter 2026 financial results and holding an earnings call on November 4, 2026.